Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics' stock has experienced significant activity and fluctuations over the past six months. The stock price increased by 15.25% in the past month and showed a year-to-date return of 254.51% as of October 24, 2025, but also saw a 7.12% decline in the 10 days leading up to October 24, 2025, and a 20.39% drop from a pivot top point on October 13, 2025. Key events impacting the stock include presentations at EASL 2025 and the American Neurological Association 2025 Annual Meeting, financial results reports, inclusion in the Russell 3000® and Russell 2000® Indexes, an Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu, acceptance of abstracts for oral presentation at AASLD - The Liver Meeting® 2025, pricing of a $135 million underwritten offering, and analyst recommendations from Raymond James and Barclays.

As a clinical-stage biopharmaceutical company, Monopar Therapeutics Inc. does not currently generate revenue from product sales, relying instead on securing funding to advance its pipeline candidates. Therefore, traditional demand seasonality is not applicable to Monopar Therapeutics at this stage of its development.

Monopar Therapeutics, Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer and rare diseases, operating within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. The company aims to advance cancer treatment by addressing unmet medical needs and improving patient outcomes through scientific innovation. Monopar's pipeline includes Validive, a clonidine hydrochloride mucobuccal tablet in Phase 2b/3 clinical trials; Camsirubicin, an analog of doxorubicin in Phase 1b clinical trials; ALXN1840 (bis-choline tetrathiomolybdate), a late-stage investigational drug for Wilson disease; MNPR-101, a urokinase plasminogen activator receptor (uPAR) targeted antibody; MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent; MNPR-101-Lu, a clinical-stage radiotherapeutic; and MNPR-101-Ac, a late-preclinical stage radiotherapeutic.

Monopar Therapeutics is headquartered in Wilmette, Illinois, United States, and conducts clinical trials in Australia for its MNPR-101 radiopharmaceuticals. The company collaborates with the Grupo Español de Investigación en Sarcomas for camsirubicin development and with the Cancer Science Institute of Singapore to evaluate MNPR-202. Its markets served are global, driven by the widespread need for effective cancer treatments.

Monopar Therapeutics has generally maintained a positive brand reputation within the investment community, with a consensus "Buy" rating from Wall Street analysts. Several analysts have initiated or maintained positive coverage. Events that have positively affected its reputation include the acceptance of abstracts for oral and poster presentations at major medical conferences and the publication of a peer-reviewed letter in the Journal of Hepatology demonstrating positive results for ALXN1840. There were no specific negative events or controversies significantly impacting Monopar Therapeutics' reputation reported in the past year.

Monopar Therapeutics Inc. has significant institutional ownership, with 101 institutional owners and shareholders holding a total of 3,344,365 shares, representing approximately 29% of the shares outstanding. Insiders own 20.50% of the company's stock, and the CEO, Chandler Robinson, directly holds 1.1% of the total shares outstanding. In the past three months, insiders have sold $35,000,067.00 in company stock, with no reported purchases.